US · Healthcare · Biotechnology
EPS came in at -0.73 against a street estimate of -0.63 — a miss of 15.9%.
Analysts rate Metagenomi, Inc. Common Stock a buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $7.00.
| Fund | Stake |
|---|---|
| Vanguard Capital Management, LLC | 2.80% |
| Renaissance Technologies Corp | 2.09% |
| Catalio Capital Management, LP | 1.40% |
| Peapod Lane Capital LLC | 1.39% |
| Two Sigma Investments LLC | 1.36% |
| Bridgeway Capital Management, LLC | 1.05% |
| Jacobs Levy Equity Management, Inc. | 1.01% |
| Geode Capital Management, LLC | 0.95% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Metagenomi, Inc. Common Stock — free to start.
Google PlayApp StoreData updated 2026-09-18.